eMedevents
  • 154,759+ Medical Conferences
  • 285 Specialties
  • 11,301 Organizers
  • 156,541 Speakers
  • 159 Countries
  • 4,789 Cities
51,586+
CME Conference Registrations Sold

SEARCH NEWS
Or

Induced Pluripotent Stem Cell Vaccine Promising for Cancer

Induced Pluripotent Stem Cell Vaccine Promising for Cancer

Fri, Feb 16, 2018

THURSDAY, Feb. 15, 2018 (HealthDay News) -- Induced pluripotent stem cell (iPSC) vaccines prevent tumor growth in syngeneic murine cancer models in a prophylactic setting, according to a study published online Feb. 15 in Cell Stem Cell.

Noting that it may be possible for iPSCs to be harnessed to elicit anti-tumor responses in cancer vaccines, Nigel G. Kooreman, M.D., from the Stanford University School of Medicine in California, and colleagues conducted a proof-of-principle study for using irradiated iPSCs in autologous anti-tumor vaccines.

The researchers found that iPSC vaccines prevented tumor growth in syngeneic murine breast cancer, mesothelioma, and melanoma models in a prophylactic setting. The iPSC vaccine inhibited melanoma recurrence at the resection site as an adjuvant and reduced metastatic tumor load, which was correlated with fewer Th17 cells and increased CD11b+GR1hi myeloid cells. Adoptive transfer of T cells isolated from tumor-bearing mice treated with the vaccine inhibited growth of tumors in unvaccinated recipients.

"Our data suggest a generalizable strategy for multiple types of cancer that could prove highly valuable in clinical immunotherapy," the authors write.

Abstract/Full Text